Get the Stockscreener App
5.44
20.89%
0.94
Camp 4 Therapeutics Corp stock is traded at $5.44, with a volume of 415.16K.
It is up +20.89% in the last 24 hours and up +22.25% over the past month.
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
See More
Previous Close:
$4.50
Open:
$4.5
24h Volume:
415.16K
Relative Volume:
1.96
Market Cap:
$341.21M
Revenue:
$3.50M
Net Income/Loss:
$-80.40M
P/E Ratio:
-2.1158
EPS:
-2.5711
Net Cash Flow:
$-29.83M
1W Performance:
+28.30%
1M Performance:
+22.25%
6M Performance:
+41.30%
1Y Performance:
+250.97%
1-Day Range:
$4.21
$5.48
1-Week Range:
$4.09
$5.48
52-Week Range:
$1.41
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
5.44 | 284.13M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Rodman & Renshaw | Buy |
| Oct-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-16-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-27-25 | Initiated | Wedbush | Outperform |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
Balyasny group discloses 4.99% Camp4 Therapeutics (CAMP) position with warrant blocker - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
CAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates - scanx.trade
CAMP4 Therapeutics (Nasdaq: CAMP) widens loss as derivative liability surges - Stock Titan
CAMP4 Therapeutics (CAMP) widens Q2 2026 loss, boosts cash runway to 2028 - Stock Titan
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
Camp4 Therapeutics Corp SEC Filing (Aug 13, 2026) - Stock Titan
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Trails Edge reports 6% Camp4 Therapeutics stake (CAMP) totaling 3.79M shares - Stock Titan
CAMP4 Therapeutics Corp expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Camp4 Therapeutics Corp CEO to launch new SYNGAP1 clinical trial in upcoming initiative - Traders Union
Yuri Maricich Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - MarketBeat
CAMP4 Therapeutics (NASDAQ:CAMP) CEO Josh Mandel-Brehm Purchases 6,551 Shares - MarketBeat
Richard Young Buys 16,378 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - MarketBeat
Insider Buying: CAMP4 Therapeutics (NASDAQ:CAMP) CFO Buys $10,809.15 in Stock - MarketBeat
5AM Ventures group updates CAMP4 Therapeutics (CAMP) stake and warrant terms - Stock Titan
CAMP4 closes $50.1 million second tranche of private placement By Investing.com - Investing.com India
CAMP4 Therapeutics Secures $50 Million Private Financing - TipRanks
Camp4 Therapeutics Raises $50.1 Million in Second Closing of Private Placement - TradingView
CAMP4 Therapeutics (Nasdaq: CAMP) raises $50.1M in second private placement closing - Stock Titan
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement - GlobeNewswire
Camp4 Therapeutics Corp leverages regulatory RNA to target genetic root causes - Traders Union
CAMP4 Therapeutics Corporation Revenue Breakdown – NASDAQ:CAMP - TradingView
CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Forecasts - Yahoo! Finance Canada
Analysts Are Bullish on These NA Stocks: SpaceX (SPCX), CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail
Camp4 Moves Into Human Trials -- The Upside Is Underpriced (NASDAQ:CAMP) - Seeking Alpha
CAMP4 receives Australian clearance for SYNGAP1 therapy trial By Investing.com - Investing.com UK
CAMP4 THERAPEUTICS CORPORATION (CAMP) stock price, news, quote and history - Yahoo Finance UK
Camp4 Therapeutics’ lead ASO approved for clinical trials in Australia - BioWorld News
CAMP4 receives Australian clearance for SYNGAP1 therapy trial - Investing.com Australia
Camp4 Therapeutics Corp secures clinical trial approval for first SYNGAP1 disease-modifying therapy in Australia - Traders Union
CAMP4 Therapeutics (CAMP) clears CMP-002 trial in Australia, eyes $50.1M raise - Stock Titan
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder - globenewswire.com
CAMP4 Therapeutics Corp (CAMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CAMP4 Therapeutics Corp (CAMP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CAMP|CAMP4 Therapeutics Corp|Price:3.440|Chg%:+0.280 - TradingKey
CAMP|CAMP4 Therapeutics Corp|Price:3.160|Chg%:+0.150 - TradingKey
CAMP4 Therapeutics Corp (CAMP) Cash Flow - TradingKey
TradingKey - TradingKey
CAMP4 Therapeutics Corp (CAMP) Income Statement - TradingKey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation - Moomoo
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
We Think Camp4 Therapeutics (NASDAQ:CAMP) Can Afford To Drive Business Growth - Sahm
New strong sell stocks for July 16th - MSN
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CAMP4 Therapeutics grants inducement stock options to new employee - scanx.trade
New Strong Sell Stocks for July 16th - The Globe and Mail
CAMP News | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
CAMP Q1 2026 Earnings: EPS Surprise Misses Estimates as Company Navigates Early-Stage Pipeline - dars.gov.et
CAMP Q1 2026 Earnings: Wider-Than-Expected Loss Despite 2% Stock UptickEarnings Seasonality - dars.gov.et
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):